Introduction {#Sec1}
============

Nonvertebral fractures, including hip fractures, represent 75 % of all fragility fractures related to osteoporosis and are associated with significant morbidity and mortality \[[@CR1]--[@CR3]\]. In randomized placebo-controlled trials, nonvertebral fracture risk reduction in the range of 20 %--30 % over 3 years has been shown with denosumab and some (zoledronic acid, alendronate, risedronate), though not all, bisphosphonates \[[@CR4]--[@CR7]\].

Only a few studies evaluating the long-term efficacy of osteoporosis drugs are available. Bisphosphonate treatment extended beyond 3 years is generally associated with a plateau in hip bone mineral density (BMD) gains and fracture rates that remain comparable to those observed during the first 3 years; however, the number of subjects in these extension studies is limited, and evidence for further reduction in nonvertebral fracture rates with continued bisphosphonate therapy has not been reported \[[@CR8]--[@CR10]\]. Hence, while treatment with a bisphosphonate for more than 3 years may seem logical to prevent further deterioration of skeletal integrity in those who remain at high risk of fracture, the actual benefit of long-term antiresorptive (bisphosphonate) therapy has been questioned \[[@CR11]\]. Larger studies are therefore needed to evaluate the fracture outcomes of long-term treatment for osteoporosis.

Denosumab (Prolia®, Amgen Inc., Thousand Oaks, CA) is a fully human monoclonal antibody that binds with high affinity and specificity to RANK ligand and prevents the formation, function, and survival of osteoclasts \[[@CR12], [@CR13]\]. In the pivotal [F]{.ul}racture [RE]{.ul}duction [E]{.ul}valuation of [D]{.ul}enosumab in [O]{.ul}steoporosis every 6 [M]{.ul}onths (FREEDOM) trial, denosumab reduced the incidence of vertebral, nonvertebral, and hip fractures over 3 years compared with placebo \[[@CR7]\]. The effect of long-term denosumab treatment on fracture risk is being evaluated for a total of 10 years in an ongoing open-label FREEDOM extension. Six years of denosumab treatment produced continued increases in BMD, maintained the dynamic reduction in bone turnover markers, and was associated with a persistent low incidence of fractures, which was significantly lower than in a control group of modeled *virtual twins* \[[@CR14], [@CR15]\].

To further evaluate long-term fracture rates using each subject as her own control, we considered the subjects who enrolled in the FREEDOM extension, who missed no more than one denosumab injection during their first 3 years of denosumab treatment (in FREEDOM for those in the original denosumab group or in the extension for those in the original placebo group), and who continued into their fourth year of denosumab treatment. By this time, women in the original FREEDOM denosumab group (long-term subjects) had completed up to 7 years of treatment. We hypothesized that denosumab treatment continued beyond year 3 was associated with a further reduction in nonvertebral fracture rate compared with the first 3 years of treatment. Since previous reports documented that gains in hip BMD accounted for a large proportion of the effect of denosumab to reduce nonvertebral fractures \[[@CR16]\], we also explored the relationship between hip BMD level attained at the end of 3 years of denosumab administration---as measured by femoral neck T-score---and subsequent nonvertebral fracture rates with longer-term denosumab administration.

Materials and methods {#Sec2}
=====================

Study design and procedures {#Sec3}
---------------------------

Both the FREEDOM (ClinicalTrials.gov: NCT00089791) and the extension (ClinicalTrials.gov: NCT00523341) study designs and main results have been previously described \[[@CR7], [@CR14], [@CR15]\]. In summary, FREEDOM was a phase 3, multinational, randomized, double-blind, placebo-controlled, 3-year study in postmenopausal women aged 60--90 years who had a lumbar spine or total hip T-score \<−2.5 at either location and ≥−4.0 at both skeletal sites. Participants were randomly assigned to receive placebo or 60 mg denosumab (Prolia®, Amgen Inc., Thousand Oaks, CA) subcutaneously every 6 months for 3 years and were required to take calcium (≥1 g) and vitamin D (≥400 IU) daily. Women who completed the FREEDOM study (i.e., completed their 3-year visit, did not miss \>1 dose of the investigational product \[IP\]) and did not receive other medications known to affect bone metabolism were invited to enroll in an extension study, during which all participants received open-label denosumab 60 mg subcutaneously every 6 months with daily calcium and vitamin D \[[@CR7]\]. Subjects who were randomized to denosumab in FREEDOM and continued denosumab treatment in the extension constitute the *long-term group* and subjects who were randomized to placebo treatment for 3 years and then started denosumab at the beginning of the extension constitute the *cross-over group*. By design, subjects were enrolled in the extension provided they had received at least five out of six denosumab or placebo doses over 3 years in FREEDOM. To ensure comparability between groups in the present analysis, we evaluated only those subjects in the cross-over group who received at least five out of six doses in their first 3 years of denosumab treatment and continued into their fourth year (the same criterion required for subjects originally assigned to denosumab to be eligible for and then enter the extension). The study protocol was approved by an institutional review board or ethics committee for each investigative site. Participants provided written informed consent.

Study visits occurred at baseline and every 6 months for the duration of the extension study. The study procedures were previously described \[[@CR15]\] and followed the same collection rigor as during FREEDOM. All nonvertebral fractures required confirmation by diagnostic imaging or a radiologist's report and were adjudicated by a central vendor (Synarc), as previously described \[[@CR7]\]. Hip BMD, as measured by dual-energy X-ray absorptiometry, was obtained in all subjects in FREEDOM, as previously reported \[[@CR7], [@CR17]\].

Statistical analyses {#Sec4}
--------------------

Analyses were implemented on subjects who enrolled in the FREEDOM extension, who missed ≤1 dose of denosumab during their first 3 years of denosumab treatment, and who continued into their fourth year of denosumab treatment (*n* = 2,343 long-term, *n* = 1,731 cross-over). Yearly incremental estimates of the incidence of nonvertebral fractures were calculated using Kaplan-Meier methodology for both groups separately. Nonvertebral fracture rates per 100 participant-years during the first 3 years and the subsequent fourth year of denosumab treatment were computed and compared based on the rate ratio (year 4 versus years 1--3) in the long-term and cross-over groups separately and combined. For the long-term group, the nonvertebral fracture rate between years 4--7 of denosumab treatment also was computed and compared with the rate during the first 3 years (years 4--7 versus years 1--3).

Nonvertebral fracture rates (per 100 participant-years), rate ratios, and 95 % confidence intervals (CIs) were computed by generalized estimating equation Poisson regression. Rate ratios were adjusted for age, total hip T-score, weight, and history of nonvertebral fractures at the start of denosumab treatment (i.e., FREEDOM baseline for the long-term group and extension study baseline for the cross-over group). The treatment group variable was included in the model for the combined analysis.

Reductions in nonvertebral fracture rates during the fourth year versus years 1--3 of denosumab treatment were also evaluated in the combined group, based on the femoral neck T-score attained after the first 3 years of denosumab administration, for each of the clinically established and used densitometric categories (osteoporosis, low bone density, and normal) using the statistical methods described above.

Results {#Sec5}
=======

Study participants {#Sec6}
------------------

Of 5,928 women eligible for the extension study, 4,550 (77 %) enrolled (*n* = 2,343 long-term; *n* = 2,207 cross-over). Of these, 4,074 women (*n* = 2,343 long-term; *n* = 1,731 cross-over) missed ≤1 dose of denosumab in their first 3 years of denosumab treatment, continued into the fourth year of treatment, and were included in this analysis, representing up to 7 years of denosumab treatment in the long-term group and 4 years of denosumab treatment in the cross-over group (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Subject disposition in the FREEDOM study and its extension and the nonvertebral fracture analysis. Subjects included in the nonvertebral fracture analysis cohort enrolled in the FREEDOM extension, missed ≤1 dose of denosumab during their first 3 years of denosumab treatment (whether during FREEDOM or the extension), and continued their fourth year of denosumab treatment. *Gray boxes* indicate subjects receiving denosumab. *Asterisk*: Two women who discontinued denosumab also entered the extension in the long-term denosumab group. *NVFX* = nonvertebral fractures

Participant characteristics at FREEDOM baseline for the cohort examined here were similar to those of the original FREEDOM population (Table [1](#Tab1){ref-type="table"}). A larger proportion of cross-over participants were ≥75 years old at the start of denosumab treatment, as the study had proceeded for 3 years from the original FREEDOM study baseline.Table 1Baseline demographicsThis study cohortFull FREEDOM population at baseline\
*N* = 7,808NVFX cohort at FREEDOM baseline\
*N* = 4,074Long-term subjects at FREEDOM baseline^a^\
*N* = 2,343Cross-over subjects at extension baseline^a^\
*N* = 1,731Age, years72.3 (5.2)71.6 (4.9)71.9 (5.0)74.3 (4.9)Age groups \-- *n* (%) ≥65 years7,394 (94.7)3,819 (93.7)2,209 (94.3)1,681 (97.1) ≥75 years2,471 (31.6)1,082 (26.6)662 (28.3)842 (48.6)Years since menopause24.2 (7.5)23.4 (7.2)23.7 (7.3)26.1 (7.2)Prevalent vertebral fractures \-- *n* (%)1,844 (23.6)927 (22.8)559 (23.9)421 (24.3)Prevalent nonvertebral fractures at age ≥55 \-- *n* (%)2,340 (30.0)1,198 (29.4)702 (30.0)578 (33.4)Lumbar spine T-score−2.83 (0.69)−2.84 (0.67)−2.83 (0.67)−2.83 (0.75)Total hip T-score−1.90 (0.81)--1.84 (0.79)−1.85 (0.79)−1.92 (0.80)Femoral neck T-score−2.16 (0.72)−2.10 (0.71)−2.11 (0.71)−2.13 (0.71)CTX^b^ (ng/mL) \-- median (Q1, Q3)0.516 (0.389, 0.702)0.533 (0.355, 0.674)0.505 (0.357, 0.700)0.496 (0.413, 0.662)P1NP^b^ (μg/L) \-- median (Q1, Q3)46.5 (36.0, 61.2)46.2 (32.6, 59.5)46.2 (31.5, 56.8)48.6 (35.0, 62.2)Data are means with standard deviations unless otherwise noted*BMD* bone mineral density, *CTX* C-terminal telopeptide of type 1 collagen, *N* number of participants enrolled in the extension study, *NVFX* nonvertebral fractures, *P1NP* procollagen type 1 N-terminal propeptide^a^Represents characteristics at the time of denosumab treatment start^b^Data are from participants who were included in the bone turnover marker substudy

Yearly incidences of nonvertebral fractures {#Sec7}
-------------------------------------------

The yearly nonvertebral fracture incidences during the first 3 years of denosumab were similar in both the cross-over and long-term groups with an observed decrease in fracture incidence in year 4 for both groups (Fig. [2](#Fig2){ref-type="fig"}). Analysis of the long-term completers group (*N* = 1,867) demonstrated similar results with a decrease in fracture incidence between years 3 (2.0 %) and 4 (1.2 %). There was also a low incidence of year-after-year hip fractures with long-term denosumab treatment in the FREEDOM extension of 0.3 % or less every year after the initial 3 years of denosumab administration.Fig. 2Yearly incidence of nonvertebral fractures in the post hoc analysis participants. **a** Yearly incidence of nonvertebral fractures through 4 years of denosumab treatment for the cross-over group. **b** Yearly incidence of nonvertebral fractures through 7 years for the long-term denosumab group in the long-term participants. Percentages for nonvertebral fractures are Kaplan-Meier estimates. *DMAb* = denosumab, *n* = number of subjects who have ≥1 nonvertebral fracture

For the entire cohort of women receiving denosumab, the nonvertebral fracture rate per 100 participant-years was reduced by 36 % (rate ratio = 0.64; *p* = 0.003) in year 4 compared with the first 3 years (Fig. [3a](#Fig3){ref-type="fig"}). A reduction of 49 % (rate ratio = 0.51; *p* = 0.005) in the nonvertebral fracture rate for year 4 compared with years 1--3 was observed in the cross-over group (Fig. [3b](#Fig3){ref-type="fig"}). In the long-term group (i.e., those who have received up to 7 years of denosumab), the nonvertebral fracture rate was reduced by 25 % (rate ratio = 0.75; *p* = 0.127) in year 4 compared with years 1--3; a similar reduction of 21 % (rate ratio = 0.79; *p* = 0.0046) was observed when the nonvertebral fracture rate during years 4--7 was compared with years 1--3 (Fig. [3c](#Fig3){ref-type="fig"}).Fig. 3Nonvertebral fracture rate ratios. **a** All denosumab-treated participants. **b** Cross-over participants. **c** Long-term participants. *N* = number of subjects who completed FREEDOM (i.e., completed their 3-year visit and did not discontinue IP), missed ≤1 dose of IP in FREEDOM, and who enrolled in the extension. In addition, cross-over subjects completed 3 years of the extension and missed ≤1 dose of denosumab during the first 3 years of the extension. Fracture rates and rate ratios were obtained using generalized estimating equation Poisson models; fracture rates are per 100 participant-years. Rate ratios relative to the first 3 years of denosumab treatment were adjusted for age, total hip T-score, weight, and history of nonvertebral fracture. In addition, the treatment group variable was included in the model for the combined analysis only

We next evaluated the influence of the BMD level attained after 3 years of denosumab treatment on the subsequent nonvertebral fracture risk reduction in the combined group. In subjects whose femoral neck T-scores remained ≤−2.5, a significant further reduction in nonvertebral fractures was observed in year 4 (rate ratio = 0.37; *p* = 0.008; Fig. [4](#Fig4){ref-type="fig"}). A further, but less pronounced, reduction in the nonvertebral fracture rate was also observed in subjects with T-scores \>−2.5 and \<−1.0 but not in subjects with T-scores ≥−1.0 (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Effect of femoral neck T-score on nonvertebral fracture rates in year 4 compared with years 1--3. *Circles* are rate ratios and *lines* indicate 95 % confidence intervals for the comparison of nonvertebral fracture rate per 100 participant-years for years 1--3 of denosumab treatment versus year 4 in the combined cohort overall and for subgroups determined by femoral neck T-score at the end of 3 years of denosumab treatment. *Asterisk*: 398 subjects did not have BMD data available at the end of year 3 of denosumab treatment

Similar observations were noted when total hip T-score was used instead of femoral neck T-score, with rate ratios of 0.85 (0.46--1.60) for the ≤−2.5 group, 0.47 (0.30--0.73) for the \>−2.5 to \<−1.0 group, and 1.22 (0.67--2.25) for the ≥−1.0 group. The rate ratio of 0.85 did not reach significance which may have been the result of the small number of subjects (*N* = 483) and the low number of fractures (*n* = 12) in this subgroup.

Discussion {#Sec8}
==========

With 4,074 participants, the cohort forming the basis of this report represents more than 50 % of the original FREEDOM study subjects and is the largest extension study to date in the field of osteoporosis. Notably, despite aging of the subjects, the nonvertebral fracture rate during year 4 was significantly further decreased compared with the first 3 years of denosumab treatment. This pattern was observed in the overall cohort and similarly in both the subjects who received denosumab for 7 years, starting in FREEDOM, and for the group who started denosumab 3 years later, allowing a confirmatory evaluation. Moreover, the nonvertebral fracture rate was significantly lower in years 4--7 compared with years 1--3 in subjects who received denosumab for 7 years. This constitutes the first observation of a further benefit of an antiresorptive therapy on nonvertebral fractures beyond 3 years of initial administration.

Extension studies with other antiresorptive drugs have not shown increases in hip BMD or incremental reductions in nonvertebral fracture rates beyond those observed in the first few years of treatment. For example, results from the Vertebral Efficacy With Risedronate Therapy-North America (VERT-NA) trial with risedronate found no significant reduction in the rate of nonvertebral fractures in 2 years of additional risedronate treatment versus the first 3 years of treatment \[[@CR10]\]. Similarly, the Fracture Intervention Trial Long-Term Extension (FLEX) study did not find a significant difference between the cumulative risk of nonvertebral fractures for postmenopausal women continuing alendronate for 5 more years beyond the initial 5 years of treatment \[[@CR9], [@CR18]\]. More recently, the extension of the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT) documented that 6 years of treatment with zoledronic acid resulted in no significant differences in nonvertebral fracture incidence compared with the first 3 years of treatment nor compared with placebo during the extension \[[@CR8]\]. Although nonvertebral fracture rates in the extension studies with alendronate and zoledronic acid were reported for those women who entered the extension and therefore were applicable to only a subset of those enrolled in the 3-year pivotal studies, the rates of nonvertebral fracture in the first 3 years were similar to those seen through the completion of both extension studies \[[@CR4]--[@CR6], [@CR19]\]. These extension studies were not adequately powered for nonvertebral fracture endpoints.

Data on nonvertebral fractures with long-term denosumab treatment appear to show a different pattern. Indeed, our analyses suggest that continuing denosumab treatment beyond 3 years reduces the nonvertebral fracture rate compared with the first 3 years of treatment. Denosumab effects that may contribute to this distinctive observation include documented rapid, marked, and sustained reductions in bone resorption markers following each denosumab dose, and progressive gains in BMD reported with up to 8 years of continuous denosumab administration, decreases in cortical porosity with corresponding increases in cortical bone mass, and increases in cortical and trabecular strength as detailed with denosumab in clinical and animal studies \[[@CR14], [@CR20]--[@CR26]\].

In our study, the mean age of women starting denosumab was 72 years for the long-term group and 74 years for those starting denosumab in the cross-over extension group, populations in which one would expect an increasing risk of fracture over time due to the skeletal deterioration associated with aging \[[@CR27], [@CR28]\]. Yet, long-term treatment with denosumab was instead associated with further nonvertebral fracture risk reduction over that documented during the first 3 years of therapy. Importantly, the pattern of decrease was similar in both groups, despite the older age of the women in the cross-over group.

The risk of a fracture is dependent on the amount and distribution of the bone mass at the skeletal site as well as the frequency and characteristics of the associated trauma, as exemplified by the variable forces that are associated with each fall \[[@CR29]\]. There are no biological reasons to suspect an effect of denosumab on fall risk or characteristics of falling, whereas continued BMD increases are observed over time with denosumab treatment. Thus, it is plausible that the further reduction in fractures observed after 3 years of denosumab administration could be attributed to a larger proportion of subjects achieving a BMD value needed to reduce the factor of risk for fracture \[[@CR30]\].

Acknowledging that factors such as actual change in BMD, body mass index, bone turnover rate, genetic predisposition, and frailty also contribute to fracture risk in the individual patient, our analysis found that fracture reductions observed in year 4 and beyond were correlated with hip BMD attained after 3 years of denosumab. Those subgroups of subjects for whom BMD remained low after 3 years of denosumab treatment had a documented additional benefit, whereas additional nonvertebral fracture risk reductions were not observed in those who had attained a normal bone density level. One explanation may be that there is a densitometric inflection point above which further gains in bone density are no longer associated with corresponding additional fracture reductions. Our data suggest that this BMD level lies between a T-score of −2.5 and −1.0, a concept also substantiated by recent work combining BMD and femoral strength by finite element analysis \[[@CR31]\]. These data also support the concept that further fracture risk reduction may be related to continued increases in hip BMD; in the original FREEDOM trial, the change in hip BMD explained a considerable amount of the reduction in nonvertebral fracture risk \[[@CR16]\].

Our study has a number of strengths including the following: (i) it has the largest population in an ongoing extension study with a planned robust assessment of fracture as an outcome; (ii) the decrease in fracture observed with the long-term group was replicated in the cross-over group that was 3 years older at the time of starting denosumab and observed within the extension phase of the study mitigating the possible impact of a cohort bias; and (iii) persistent low fracture rates were observed through year 7.

Our study also has limitations, namely that, as is the case for all extension studies, the original population may differ from the cohort of subjects enrolled in the extension study (potential selection bias) and the post hoc nature of the analyses. In particular, by design, subjects were enrolled in the extension provided they had received at least five out of six denosumab or placebo doses over 3 years in FREEDOM and at least five out of six denosumab doses in the first 3 years of the extension for the cross-over group. Hence, the further fracture risk reductions observed in year 4 of therapy and beyond may not have been observed among subjects with less than optimal persistence. In addition, while this extension enrolled a significant number of subjects, the small number of events and the year-by-year variability remind us that some degree of caution should exist in the interpretation of the data. Attrition of subjects at high risk during the extension could also influence the results; however, this is unlikely because (a) the proportion of patients who sustained a fracture and remained on study increased over time, and (b) the conclusions remain valid even if we assume a fracture rate in those who discontinued or died that is double that observed in the remaining subjects \[[@CR32]\]. Finally, these analyses cannot substitute for the results of a randomized placebo-controlled study. The need for an open-label extension study was predicated on ethical concerns for continuing placebo treatment after demonstration of denosumab anti-fracture efficacy in the FREEDOM parent study.

In summary, in the ongoing extension to the FREEDOM study, nonvertebral fracture rates were reduced during year 4 and beyond as compared with the first 3 years of denosumab administration, a period for which robust fracture reduction is already established. This observation appears distinctive to denosumab administration for patients with osteoporosis and who remain at risk for fracture based on bone densitometry. Further confirmation of the benefits for nonvertebral fracture protection in years beyond the fourth, or with regard to other clinical parameters, awaits completion of all 10 years of the FREEDOM extension study.
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